Literature DB >> 12100718

Involvement of tumour necrosis factor-alpha-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells.

Yizhi Yu1, Shuxun Liu, Wenya Wang, Wengang Song, Minghui Zhang, Weiping Zhang, Zhihai Qin, Xuetao Cao.   

Abstract

Dendritic cells (DC) are potent antigen-presenting cells (APC) specialized in T-cell mediated immune responses, and also play critical roles in the homeostasis of T cells for controlling immune responses. In the present study, we demonstrated that during mouse bone-marrow-derived DC activation of ovalbumin (OVA)-specific Ia-kb-restricted T hybridoma cells, MF2.2D9 and OVA257-264-specific H-2kb-restricted RF33.70 T cells, respectively, both hybridomas undergo cell death, partially mediated via apoptotic ligand-tumour necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand (TRAIL). Lipopolysaccharide enhanced the cytotoxic effect on the two activated T hybridoma cells, which was correlated with up-regulation of TRAIL-expression on DC to some extent. The activation of caspase-3 in activated T hybridoma cells cocultured with DC contributed to the programmed cell death pathway T cells underwent. Therefore, our results show that activation-induced cell death of T hybridoma cells can be influenced by DC, suggesting that DC may be involved in elimination of activated T cells at the end of primary immune responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100718      PMCID: PMC1782728          DOI: 10.1046/j.1365-2567.2002.01431.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells.

Authors:  D A Mitchell; S K Nair; E Gilboa
Journal:  Eur J Immunol       Date:  1998-06       Impact factor: 5.532

2.  TRAIL/Apo-2-ligand-induced apoptosis in human T cells.

Authors:  I Jeremias; I Herr; T Boehler; K M Debatin
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

3.  Early events in dendritic cell maturation induced by LPS.

Authors:  F Granucci; E Ferrero; M Foti; D Aggujaro; K Vettoretto; P Ricciardi-Castagnoli
Journal:  Microbes Infect       Date:  1999-11       Impact factor: 2.700

4.  Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.

Authors:  X D Zhang; A Franco; K Myers; C Gray; T Nguyen; P Hersey
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

5.  Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.

Authors:  M J Martínez-Lorenzo; A Anel; S Gamen; I Monle n; P Lasierra; L Larrad; A Piñeiro; M A Alava; J Naval
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

6.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells.

Authors:  K Steinbrink; H Jonuleit; G Müller; G Schuler; J Knop; A H Enk
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

7.  Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.

Authors:  X Cao; W Zhang; L He; Z Xie; S Ma; Q Tao; Y Yu; H Hamada; J Wang
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

8.  Distinct dendritic cell subsets differentially regulate the class of immune response in vivo.

Authors:  B Pulendran; J L Smith; G Caspary; K Brasel; D Pettit; E Maraskovsky; C R Maliszewski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

9.  Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells.

Authors:  M J Martínez-Lorenzo; M A Alava; S Gamen; K J Kim; A Chuntharapai; A Piñeiro; J Naval; A Anel
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

10.  CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo.

Authors:  R Maldonado-López; T De Smedt; P Michel; J Godfroid; B Pajak; C Heirman; K Thielemans; O Leo; J Urbain; M Moser
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

View more
  7 in total

1.  Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

Authors:  Collin J LaCasse; Nona Janikashvili; Claire B Larmonier; Darya Alizadeh; Neale Hanke; Jessica Kartchner; Elaine Situ; Sara Centuori; Michael Har-Noy; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

Review 2.  Following the TRAIL to apoptosis.

Authors:  Bharti R Chaudhari; Richard F Murphy; Devendra K Agrawal
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Novel immunoregulatory role of perforin-positive dendritic cells.

Authors:  Ran Orgad; Bar Nathansohn-Levi; Sivan Kagan; Yael Zlotnikov Klionsky; Yair Reisner
Journal:  Semin Immunopathol       Date:  2016-08-30       Impact factor: 9.623

4.  TNFR2 expression on non-bone marrow-derived cells is crucial for lipopolysaccharide-induced septic shock and downregulation of soluble TNFR2 level in serum.

Authors:  Shubai Liu; Lijie Rong; Jingjing Deng; Xiaopu Zhao; Xiaoman Liu; Xia Xu; Zhihai Qin
Journal:  Cell Mol Immunol       Date:  2011-01-24       Impact factor: 11.530

Review 5.  TRAIL in cancer therapy: present and future challenges.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Eric Solary; Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

Review 6.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  MiR-98 Protects Nucleus Pulposus Cells against Apoptosis by Targeting TRAIL in Cervical Intervertebral Disc Degeneration.

Authors:  Shimin Xu; Yuezhong Li; Junshan Zhang; Zhiwei Li; Yanping Xing
Journal:  J Healthc Eng       Date:  2022-01-25       Impact factor: 2.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.